Table 3.
Metrics of RECIST response, CEA response, and CA 19-9 response to different groups.
| Characteristics | MiniPDX-guided group (n = 21) | Experimental treatment group (n = 47) | p-value |
|---|---|---|---|
| RECIST 1.1 | 0.038 | ||
| CR | 0 | 0 | |
| PR | 12 (57.14%) | 12 (25.53%) | |
| SD | 6 (28.57%) | 20 (42.55%) | |
| PD | 3 (14.29%) | 15 (31.91%) | |
| ORR | 12 (57.14%) | 12 (25.53%) | 0.029 |
| DCR | 18 (85.71%) | 32 (68.08%) | 0.035 |
| CEA parameters* | 0.174 | ||
| Decrease >50% | 10 (62.50%) | 14 (37.84%) | |
| Decrease >20% | 4 (25.00%) | 12 (32.43%) | |
| Decrease <20% or increase | 2 (12.50%) | 11 (29.73%) | |
| CA 19-9 parameters# | 0.009 | ||
| Decrease >50% | 12 (70.59%) | 12 (30.0%) | |
| Decrease >20% | 2 (11.76%) | 18 (45.00%) | |
| Decrease <20% or increase | 3 (17.65%) | 10 (25.00%) |
*CEA levels were evaluated in 16 and 37 patients, respectively, in the MiniPDX-guided and control groups.
#CA19-9 levels were tested in 17 and 40 patients, respectively, in the MiniPDX-guided and control groups.
CA19-9, carbohydrate antigen 19-9; CEA, carcinoma embryonic antigen; CR, complete response; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group physical status; ORR, objective response rate; PD, progressive disease; PDX, patient-derived xenograft; PR, partial response; SD, stable disease.